Zervimesine — Safety, Research, Risks & Legal Status

Not medical advice. Zervimesine is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	CT1812; CT-1812
Category	Research Chemical
Drug class	Small-molecule sigma-2 receptor antagonist (TMEM97 complex modulator)
Sigma-2 binding affinity	Ki = 8.5 nM; approximately 100-fold selectivity over 72 other molecular targets
Development stage	Phase 2 completed for Alzheimer's disease (SHINE) and dementia with Lewy bodies (SHIMMER); Phase 3 programs in planning as of July 2025
FDA designation	Fast Track designation granted for Alzheimer's disease
Primary safety signal	Dose-dependent, reversible transient liver enzyme (ALT/AST) elevations; no clinical liver injury events reported
Patent status	Composition-of-matter patent allowance granted 2024, protection projected to 2045
US legal status	Investigational drug - not FDA approved. All human use remains experimental and restricted to authorized clinical trials. Not available for commercial use or general human consumption in the United States. Holds FDA Fast Track designation for Alzheimer's disease. End-of-Phase 2 meetings with FDA completed for both Alzheimer's disease and dementia with Lewy bodies as of July 2025, with Phase 3 programs being planned.

What is Zervimesine?

Zervimesine (development code CT1812) is a small-molecule, orally administered sigma-2 receptor antagonist developed by Cognition Therapeutics, Inc. (NASDAQ: CGTX). It is designed to displace toxic amyloid-beta and alpha-synuclein oligomers from neuronal cell-surface binding sites, thereby reducing synaptic stress and neuroinflammation. As of mid-2025, it has completed Phase 2 clinical trials in both mild-to-moderate Alzheimer's disease and dementia with Lewy bodies, with Phase 3 registrational programs in planning stages. It is also in early preclinical exploration for dry age-related macular degeneration. No definitive proof of cognitive benefit has been established; pivotal efficacy data remain pending from future Phase 3 work.

How it works

Zervimesine acts as a negative allosteric modulator at the sigma-2 receptor complex, which is composed of TMEM97, PGRMC1, and LDLR. It binds to this complex with high affinity (Ki = 8.5 nM) and approximately 100-fold selectivity over 72 other molecular targets tested, with roughly 7.4-fold lower affinity for sigma-1 receptors. By occupying the sigma-2 complex, zervimesine competitively displaces toxic amyloid-beta (Abeta) oligomers and alpha-synuclein oligomers from their neuronal membrane binding sites. This is hypothesized to reduce oligomer-mediated synaptic dysfunction, neuroinflammation, and downstream neuronal stress. Unlike amyloid-clearance approaches, the mechanism targets oligomer-receptor interaction rather than plaque burden per se. Preclinical models showed restoration of synaptic density and cognitive function, but translation to statistically robust human cognitive endpoints has not yet been demonstrated.

Background & history

CT1812 was developed by Cognition Therapeutics as part of a research program targeting the sigma-2 receptor complex and its role in mediating neurotoxic oligomer binding. Early preclinical work established that sigma-2 receptor antagonism could displace amyloid-beta oligomers from synaptic sites and restore synaptic function in animal models. The compound entered human clinical trials with Phase 1 safety work followed by two parallel Phase 2 trials: the SHINE trial (NCT03507790) in mild-to-moderate Alzheimer's disease (N=153, 36 weeks) and the SHIMMER trial (NCT05225415) in dementia with Lewy bodies (N=130, 26 weeks). Both trials met their primary safety and tolerability endpoints. The INN "zervimesine" was officially designated in 2025. FDA granted Fast Track designation for the Alzheimer's indication. End-of-Phase 2 meetings with FDA were completed by July 2025, and a composition-of-matter patent allowance with protection extending to 2045 was announced in 2024. As of mid-2025, zervimesine represents one of the few mechanistically distinct pipeline candidates for neurodegenerative disease operating outside of the amyloid-clearance paradigm.

What the research says

Phase 2 data are available but efficacy signals are exploratory and not definitive. In the SHINE trial (Alzheimer's disease, N=153), the primary cognitive endpoint (ADAS-Cog11) showed only a trend toward slowing of approximately 1 point versus placebo in the full population, which did not reach statistical significance. A pre-specified subgroup with lower baseline CSF tau showed a statistically significant slowing of 2.7 points, and CSF biomarker and EEG measures trended favorably. In the SHIMMER trial (dementia with Lewy bodies, N=130), the trial met safety and tolerability endpoints with favorable trends across cognitive, neuropsychiatric, functional, and motor measures, though these were exploratory endpoints. Biomarker substudy data (PubMed PMID: 40547328) identified potential pharmacodynamic signals in synapse and vesicle trafficking pathways. Subgroup analyses suggest patients with lower baseline plasma p-tau217 may be preferential responders (PMC: PMC12741914), informing proposed enrichment strategies for Phase 3. Dry AMD preclinical data presented at ARVO 2025 showed protection of retinal pigment epithelial cells in cell-based models - this indication remains early preclinical with no human data. Overall, the compound is mechanistically distinguished and shows promising exploratory signals, but pivotal human efficacy data remain pending.

Reported effects

Exploratory trend toward slowing of cognitive decline on ADAS-Cog11 in mild-to-moderate Alzheimer's disease (Phase 2; not statistically significant in full population)
Statistically significant slowing of cognitive decline in lower-baseline-tau subgroup of Alzheimer's patients (2.7-point difference; subgroup analysis, not primary endpoint)
Favorable exploratory trends in cognitive, neuropsychiatric, functional, and motor measures in dementia with Lewy bodies (Phase 2; exploratory endpoints only)
CSF biomarker changes consistent with modulation of synapse and vesicle trafficking pathways (pharmacodynamic signal, Phase 2 substudy)
EEG measures trended toward favorable changes in synaptic function markers (Phase 2; exploratory)
Displacement of toxic amyloid-beta and alpha-synuclein oligomers from neuronal membranes (mechanism established in preclinical models; human clinical correlate under investigation)
Preclinical protection of retinal pigment epithelial cells in dry AMD cell models (animal/cell data only; no human data)

Dosing & administration (informational)

In Phase 2 clinical trials, zervimesine was studied at oral doses of 100 mg once daily and 300 mg once daily versus placebo. Both trials were 100 mg QD and 300 mg QD arms. The 100 mg dose showed a more favorable tolerability profile in the SHIMMER trial. These ranges are cited for informational and reference purposes only, drawn from published clinical trial protocols. This is an unapproved investigational drug; no dosing information should be interpreted as a protocol or recommendation. Anyone with questions about treatment options should consult a licensed clinician or refer to active clinical trial enrollment criteria at ClinicalTrials.gov.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Primary safety concern: dose-dependent transient elevations of liver enzymes (ALT/AST), observed in Phase 2 trials
Liver enzyme elevations were reversible upon drug discontinuation; no clinical liver injury events reported in Phase 2
Higher discontinuation rates at 300 mg QD dose (16.3% in SHIMMER) versus 100 mg QD (4.5%) and placebo (4.8%), suggesting dose-dependent tolerability issues
Overall tolerability described as favorable across both SHINE and SHIMMER trials; no serious adverse events attributed to drug were reported in available summaries
Long-term safety data beyond 36 weeks (SHINE) and 26 weeks (SHIMMER) are not yet available
All safety data derive from controlled clinical trial settings; safety profile outside controlled conditions is unknown
Not approved for human use outside of clinical trials; risks in unsupervised settings are undefined

Drug & supplement interactions

N
o
f
o
r
m
a
l
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
o
r
r
e
p
o
r
t
e
d
i
n
a
v
a
i
l
a
b
l
e
P
h
a
s
e
2
d
a
t
a
s
u
m
m
a
r
i
e
s
a
s
o
f
J
u
l
y
2
0
2
5
.
G
i
v
e
n
t
h
e
o
b
s
e
r
v
e
d
d
o
s
e
-
d
e
p
e
n
d
e
n
t
l
i
v
e
r
e
n
z
y
m
e
e
l
e
v
a
t
i
o
n
s
,
c
a
u
t
i
o
n
r
e
g
a
r
d
i
n
g
c
o
-
a
d
m
i
n
i
s
t
r
a
t
i
o
n
w
i
t
h
o
t
h
e
r
h
e
p
a
t
i
c
a
l
l
y
m
e
t
a
b
o
l
i
z
e
d
c
o
m
p
o
u
n
d
s
o
r
h
e
p
a
t
o
t
o
x
i
c
a
g
e
n
t
s
w
o
u
l
d
b
e
e
x
p
e
c
t
e
d
t
o
b
e
r
e
l
e
v
a
n
t
,
t
h
o
u
g
h
n
o
s
p
e
c
i
f
i
c
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
a
v
a
i
l
a
b
l
e
.
P
o
t
e
n
t
i
a
l
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
s
i
g
m
a
-
1
r
e
c
e
p
t
o
r
l
i
g
a
n
d
s
(
i
n
c
l
u
d
i
n
g
c
e
r
t
a
i
n
a
n
t
i
d
e
p
r
e
s
s
a
n
t
s
a
n
d
o
p
i
o
i
d
s
)
a
r
e
m
e
c
h
a
n
i
s
t
i
c
a
l
l
y
p
l
a
u
s
i
b
l
e
g
i
v
e
n
t
h
e
c
o
m
p
o
u
n
d
'
s
r
o
u
g
h
l
y
7
.
4
-
f
o
l
d
l
o
w
e
r
b
u
t
n
o
n
-
n
e
g
l
i
g
i
b
l
e
a
f
f
i
n
i
t
y
f
o
r
s
i
g
m
a
-
1
r
e
c
e
p
t
o
r
s
;
n
o
c
l
i
n
i
c
a
l
d
a
t
a
o
n
t
h
i
s
e
x
i
s
t
.
I
n
t
e
r
a
c
t
i
o
n
d
a
t
a
r
e
m
a
i
n
t
o
b
e
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
P
h
a
s
e
3
p
r
o
g
r
a
m
s
.

Who should avoid it

Use outside of authorized clinical trial settings - this is an unapproved investigational drug
Self-administration or sourcing from non-clinical channels; compound is not commercially available
Combining with known hepatotoxic agents given observed liver enzyme elevations, until interaction data are available
Use in individuals with pre-existing liver disease, given the observed ALT/AST signal (no formal contraindication data published, but prudence warranted)
Assuming Phase 2 exploratory trends represent confirmed clinical benefit - pivotal Phase 3 data are pending
Interpreting subgroup analyses (lower tau, lower p-tau217 enrichment) as established patient selection criteria

How it is commonly combined

No stacking or combination data exist for zervimesine. Its mechanism - sigma-2 receptor antagonism to displace toxic oligomers - is mechanistically distinct from anti-amyloid monoclonal antibodies (lecanemab, donanemab), tau-targeting therapies, and cholinesterase inhibitors. Cognition Therapeutics has noted the complementary potential of combining an oligomer-displacement mechanism with amyloid-clearance approaches, but no combination clinical data have been reported. Any combination use would be strictly within clinical trial protocols only.

Legal & regulatory. Investigational drug - not FDA approved. All human use remains experimental and restricted to authorized clinical trials. Not available for commercial use or general human consumption in the United States. Holds FDA Fast Track designation for Alzheimer's disease. End-of-Phase 2 meetings with FDA completed for both Alzheimer's disease and dementia with Lewy bodies as of July 2025, with Phase 3 programs being planned.

Quality & harm reduction

Z
e
r
v
i
m
e
s
i
n
e
i
s
a
n
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
p
h
a
r
m
a
c
e
u
t
i
c
a
l
c
o
m
p
o
u
n
d
s
y
n
t
h
e
s
i
z
e
d
a
n
d
c
h
a
r
a
c
t
e
r
i
z
e
d
b
y
C
o
g
n
i
t
i
o
n
T
h
e
r
a
p
e
u
t
i
c
s
u
n
d
e
r
I
N
D
(
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
n
e
w
d
r
u
g
)
r
e
g
u
l
a
t
o
r
y
o
v
e
r
s
i
g
h
t
.
I
t
i
s
n
o
t
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
.
P
u
r
i
t
y
,
s
y
n
t
h
e
s
i
s
r
o
u
t
e
,
a
n
d
f
o
r
m
u
l
a
t
i
o
n
d
e
t
a
i
l
s
a
r
e
g
o
v
e
r
n
e
d
b
y
c
l
i
n
i
c
a
l
-
g
r
a
d
e
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
t
a
n
d
a
r
d
s
r
e
q
u
i
r
e
d
f
o
r
I
N
D
-
f
i
l
e
d
s
t
u
d
i
e
s
.
N
o
g
r
a
y
-
m
a
r
k
e
t
o
r
r
e
s
e
a
r
c
h
-
c
h
e
m
i
c
a
l
s
u
p
p
l
y
c
h
a
i
n
e
x
i
s
t
s
f
o
r
t
h
i
s
c
o
m
p
o
u
n
d
a
s
o
f
m
i
d
-
2
0
2
5
.
A
n
y
m
a
t
e
r
i
a
l
p
u
r
p
o
r
t
i
n
g
t
o
b
e
z
e
r
v
i
m
e
s
i
n
e
o
u
t
s
i
d
e
o
f
a
n
a
u
t
h
o
r
i
z
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
w
o
u
l
d
h
a
v
e
n
o
v
e
r
i
f
i
a
b
l
e
q
u
a
l
i
t
y
a
s
s
u
r
a
n
c
e
.

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find Zervimesine →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Has zervimesine been proven to slow Alzheimer's disease progression?

Not definitively. The Phase 2 SHINE trial showed only a trend toward 1-point slowing on ADAS-Cog11 in the full population, which did not reach statistical significance. A subgroup with lower baseline tau showed a statistically significant 2.7-point slowing, but subgroup analyses are hypothesis-generating, not confirmatory. Pivotal Phase 3 evidence is pending.

What dose should I take, and where can I get zervimesine?

Dosing guidance cannot be provided here, and zervimesine is not available for general use. It is an unapproved investigational drug accessible only through authorized clinical trials. Anyone interested in access should consult a clinician and review active trials at ClinicalTrials.gov (search: CT1812 or zervimesine). Do not attempt to source this compound outside of a formal trial.

How is zervimesine different from anti-amyloid antibodies like lecanemab?

Lecanemab and similar monoclonal antibodies clear amyloid plaques and soluble oligomers from the brain via immune-mediated mechanisms, requiring IV infusion and carrying risks of amyloid-related imaging abnormalities (ARIA). Zervimesine is an orally administered small molecule that does not clear amyloid but rather blocks toxic oligomers from binding to neuronal surface receptors (sigma-2 complex). The two approaches are mechanistically complementary. No head-to-head or combination data exist.

Is the liver enzyme elevation a serious concern?

In Phase 2 trials, transient elevations of ALT and AST were observed in a dose-dependent manner but reversed upon drug discontinuation, and no clinical liver injury events were reported. The signal is notable and will require monitoring protocols in Phase 3, particularly at the 300 mg dose, which showed higher discontinuation rates (16.3% in SHIMMER). Whether this signal represents a meaningful risk at the doses used in Phase 3 remains to be characterized.

Does zervimesine work in dementia with Lewy bodies?

Phase 2 SHIMMER trial (N=130, 26 weeks) met its primary safety and tolerability endpoints and showed favorable exploratory trends across cognitive, neuropsychiatric, functional, and motor measures. However, these were exploratory, not powered efficacy endpoints. The results were sufficiently encouraging for Cognition Therapeutics to plan a Phase 3 program targeting DLB psychosis specifically. Definitive efficacy has not been established.

What is the significance of p-tau217 and tau subgroup findings?

Post-hoc analyses from the SHINE and SHIMMER trials suggest that patients with lower baseline plasma p-tau217 or lower CSF tau may show more pronounced cognitive benefit from zervimesine. This is hypothesized to reflect that lower tau burden at baseline may represent a stage where synaptic protection via sigma-2 antagonism is more impactful. These are subgroup and biomarker analyses only; prospective validation in enriched Phase 3 populations is required to confirm this as a predictive biomarker strategy.

References & further reading

PubMed: zervimesine CT1812 dementia Lewy bodies Phase 2 SHIMMER trial Galvin 2025 (PMID: 41416579)
PubMed: CT1812 cerebrospinal fluid pharmacodynamic biomarkers synaptic Phase 2 substudy (PMID: 40547328)
PubMed: zervimesine CT1812 lower baseline p-tau217 Alzheimer subgroup efficacy analysis (PMC: PMC12741914)
ClinicalTrials.gov: NCT03507790 (SHINE trial - CT1812 mild-to-moderate Alzheimer's disease)
ClinicalTrials.gov: NCT05225415 (SHIMMER trial - CT1812 dementia with Lewy bodies)